Clinician’s Guide to Adverse Events Associated With High-Dose Interleukin-2

Download this PDF for guidance on the safe and effective use of HD IL-2 for patients with renal cell carcinoma.
Brendan D. Curti, MD
Format: Adobe Acrobat (.pdf)
File Size: 52 KB
Released: November 11, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Clinigen Inc.

Related Content

Von Experten verfasster Kommentar zu Kombinationstherapien mit PARP-Inhibitoren und anderen Wirkstoffen bei fortgeschrittenem Prostatakrebs von Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Commento di un esperto sulle terapie di combinazione che utilizzano inibitori PARP più altri agenti come Opzioni di cura clinica (Clinical Care Options, (CCO), nel cancro alla prostata avanzato.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

臨床ケアオプション (CCO)による、前立腺進行がんに対するRARP阻害薬と他の薬剤を使用した組み合わせ治療に関する専門家が書いたコメント

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

CCO downloadable PDF: immune checkpoint therapy for advanced urothelial cancer, perspectives from Argentina

person default Alejandro Nolazco, MD person default José Ignacio Nolazco, MD Released: March 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue